Apolipoprotein C-III (ApoC-III) is a 79-amino acid glycoprotein synthesized primarily in the liver and, to a lesser extent, in the brain. It is a component of very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and high-density lipoproteins (HDL), where it plays a critical role in regulating triglyceride metabolism by inhibiting lipoprotein lipase (LPL) and delaying hepatic uptake of triglyceride-rich lipoproteins. In the central nervous system, ApoC-III is expressed by neurons and glial cells, where it participates in brain lipid homeostasis, cholesterol transport, and neuroinflammatory responses. Emerging evidence links ApoC-III to neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, and related disorders, positioning it as both a biomarker and potential therapeutic target.
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Apolipoprotein C-III Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>APOLIPOC3</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Apolipoprotein C-III</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=APOLIPOC3" target="_blank">Search UniProt</a></td>
</tr>
</table>
Apolipoprotein C-III (ApoC-III) is a 79-amino acid glycoprotein synthesized primarily in the liver and, to a lesser extent, in the brain. It is a component of very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and high-density lipoproteins (HDL), where it plays a critical role in regulating triglyceride metabolism by inhibiting lipoprotein lipase (LPL) and delaying hepatic uptake of triglyceride-rich lipoproteins. In the central nervous system, ApoC-III is expressed by neurons and glial cells, where it participates in brain lipid homeostasis, cholesterol transport, and neuroinflammatory responses. Emerging evidence links ApoC-III to neurodegenerative diseases including Alzheimer's Disease, Parkinson's Disease, and related disorders, positioning it as both a biomarker and potential therapeutic target.
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Apolipoprotein C-III Protein</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>APOLIPOC3</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Apolipoprotein C-III</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=APOLIPOC3" target="_blank">Search UniProt</a></td>
</tr>
</table>
The APOC3 gene is located on chromosome 11q23.3 within the APOC1/APOC2/APOC4 cluster and spans approximately 3.1 kb. The gene consists of 4 exons encoding a 297 bp mRNA that translates into a 79-amino acid preproprotein containing a 20-residue signal peptide that is cleaved to yield the mature 59-residue protein. ApoC-III circulates in multiple lipoprotein fractions, with 60-70% associated with VLDL, 20-30% with HDL, and 5-10% with IDL, and this distribution changes with metabolic state: fasting increases HDL-associated ApoC-III while postprandial state increases VLDL-associated ApoC-III.
The APOC3 gene is located on chromosome 11q23.3 within the APOC1/APOC2/APOC4 gene cluster. It spans approximately 3.1 kb and contains 4 exons that encode a 297 bp mRNA. This mRNA translates into a 79-amino acid preproprotein, which includes a 20-residue signal peptide that is cleaved during processing to yield the mature 59-residue functional protein [@karathanasis1986].
ApoC-III possesses several structural features that enable its biological function [@grossman1984]. The N-terminal signal peptide (residues 1-20) targets the protein for secretion, while the mature peptide (residues 21-79) constitutes the functional domain. The protein contains a glycosylation site at Asn position 14 (N14-linked oligosaccharide) and two amphipathic helical regions (residues 28-44 and 45-66) that mediate lipid binding. The three-dimensional structure reveals a compact, globular protein with a hydrophobic core and surface-exposed hydrophilic regions that interact with lipoprotein particles.
ApoC-III circulates in multiple lipoprotein fractions including VLDL (60-70% of circulating ApoC-III), HDL (20-30%), and IDL (5-10%) [@scv2003]. The distribution of ApoC-III among these lipoprotein fractions changes with metabolic state. During fasting, HDL-associated ApoC-III increases, while in the postprandial state, VLDL-associated ApoC-III predominates. This dynamic redistribution reflects the protein's role in responding to metabolic demands and its functional interplay with various lipoprotein particles.
ApoC-III serves as a key regulator of triglyceride levels through multiple interconnected mechanisms [@wang2001]. Regarding lipoprotein lipase inhibition, ApoC-III directly binds to LPL, competes with apolipoprotein C-II (the LPL activator), and reduces the enzyme's catalytic efficiency. For hepatic uptake modulation, ApoC-III inhibits triglyceride-rich lipoprotein binding to lipoprotein receptors, blocks interaction with LDL receptor family members, and delays remnant particle clearance. In VLDL metabolism, ApoC-III regulates production and secretion, modulates particle size, and influences conversion to IDL and LDL.
In the central nervous system, ApoC-III participates in multiple aspects of lipid homeostasis [@mahley2015]. For cholesterol transport, ApoC-III contributes to brain-specific HDL-like particle formation, neuronal cholesterol efflux, and the astrocyte-neuron cholesterol shuttle. Regarding myelin maintenance, ApoC-III affects the lipid composition of myelin sheaths, oligodendrocyte lipid synthesis, and white matter integrity. In synaptic function, ApoC-III influences synaptic membrane lipid composition, neurotransmitter release regulation, and dendritic spine morphology.
ApoC-III exhibits complex immunomodulatory effects that are still being characterized [@koch2015]. The protein inhibits monocyte activation, modulates cytokine production, affects macrophage foam cell formation, and regulates TLR signaling pathways. These anti-inflammatory properties suggest that ApoC-III may play a protective role in neuroinflammatory contexts, though the precise mechanisms remain under investigation.
ApoC-III contributes to Alzheimer's disease pathogenesis through multiple interconnected mechanisms [@tong2015][@zhang2016]. In terms of lipid metabolism dysregulation, elevated serum ApoC-III has been documented in AD patients, correlating with CSF Aβ42 levels and brain atrophy patterns, and showing association with vascular contributions to dementia. For amyloid processing, ApoC-III interacts with Aβ peptides, modulates aggregation and clearance, influences amyloid plaque composition, and affects cerebral amyloid angiopathy. Lipid raft alterations include membrane microdomain disruption, modified APP processing in lipid rafts, synaptic membrane abnormalities, and neuronal signal transduction deficits. Inflammatory responses feature enhanced microglial activation, cytokine dysregulation, neurovascular unit dysfunction, and blood-brain barrier alterations.
In Parkinson's disease, ApoC-III plays roles in dopaminergic neuron biology that are still being elucidated [@liang2017]. The protein can bind to α-synuclein and modulate its aggregation kinetics, potentially influencing Lewy body composition and prion-like propagation. Lipid homeostasis disruption manifests as altered brain lipid profiles in PD, changes in neuronal membrane composition, mitochondrial lipid alterations, and endoplasmic reticulum stress. Neuroinflammation is evidenced by microglial activation markers, cytokine expression changes, and peripheral immune-brain crosstalk.
ApoC-III contributes to vascular contributions to cognitive impairment and dementia (VCID) through several mechanisms [@sordi2020]. These include promotion of small vessel disease progression, increased white matter hyperintensity burden, alterations in cerebrovascular reactivity, and enhanced ischemic injury susceptibility.
Targeting ApoC-III represents a novel therapeutic approach with emerging evidence from multiple lines of investigation [@scv2003]. Genetic studies have shown that APOC3 loss-of-function variants are associated with reduced cardiovascular risk and that protective variants correlate with lower dementia risk, with gene dosage effects on disease progression being observed. Pharmacological targeting strategies include antisense oligonucleotides (ASOs) that reduce ApoC-III, monoclonal antibodies in development, and small molecule inhibitors under investigation.
Several APOC3 polymorphisms have been associated with disease phenotypes [@willer2013]. The rs2854116 variant shows association with triglyceride levels, while rs2854117 is linked to AD risk. The rs4420638 represents an APOE/APOC1 cluster variant, and rs739566 shows association with metabolic syndrome.
Loss-of-function variants in APOC3 are associated with reduced triglycerides and potential protection from related diseases, whereas gain-of-function variants confer hypertriglyceridemia risk.
APOC3 variant frequency varies by ancestry, with certain populations showing selection signatures and evolutionary implications for lipid metabolism genes.
ApoC-III has emerged as a promising biomarker for neurodegenerative disease, with studies examining both peripheral and cerebrospinal fluid measurements [@song2015]. For blood-based biomarkers, serum ApoC-III is elevated in AD patients, correlates with disease severity, and shows predictive value for progression, making it useful in combination biomarker panels. Regarding CSF biomarkers, studies have examined CSF ApoC-III levels comparing AD patients to controls, with correlation to neuroimaging markers and relationship to cognitive performance being evaluated. Imaging correlations include associations with brain atrophy patterns, white matter hyperintensities, and cerebral amyloid angiopathy findings.
Several therapeutic modalities are being explored to target ApoC-III. Antisense oligonucleotides such as volanesorsen (ISIS 304137) have been shown to reduce ApoC-III and triglycerides, though CNS penetration remains a challenge. Monoclonal antibodies targeting ApoC-III for binding and neutralization offer subcutaneous administration options with safety profiles under study. Small molecules including LPL modulators, nuclear receptor agonists, and metabolic pathway targeting agents are also under investigation.
Key challenges in developing ApoC-III-targeted therapies include blood-brain barrier penetration, distinguishing brain-specific versus peripheral ApoC-III functions, establishing long-term safety profiles, and developing appropriate patient selection criteria.
Researchers have developed several transgenic models to study ApoC-III function, including APOC3 overexpression models, APOC3 knockout models, and humanized mouse models that express human APOC3 in a mouse background.
ApoC-III transgenic and knockout models exhibit hypertriglyceridemia, altered lipoprotein profiles, and various brain phenotypes that are being characterized to understand the protein's roles in both systemic and neural lipid metabolism.
ApoC-III interacts with several key proteins in lipid metabolism pathways [@huang2015]. It inhibits lipoprotein lipase activity, modulates hepatic lipase function, blocks binding to LDL receptor family members, and competes with apolipoprotein E in lipid binding.
ApoC-III participates in multiple metabolic pathways including triglyceride hydrolysis, VLDL metabolism, cholesterol efflux, and HDL remodeling.
Several critical questions remain unanswered regarding ApoC-III biology and its role in neurodegeneration. These include distinguishing brain-specific versus peripheral ApoC-III functions, understanding temporal dynamics in disease progression, elucidating mechanisms of neuroprotection, and determining optimal biomarker combinations.
Priority areas for future research include developing brain-penetrant therapeutic agents, conducting biomarker validation studies, performing additional genetic association studies, and conducting detailed mechanistic investigations of ApoC-III function in the brain.
Apolipoprotein C-III represents a critical nexus between systemic lipid metabolism and brain health. Its roles in triglyceride regulation, neuroinflammation, and lipid homeostasis link it to multiple neurodegenerative disease pathways. While much remains to be learned about brain-specific ApoC-III functions, the emerging evidence positions it as a promising target for biomarker development and therapeutic intervention in Alzheimer's disease, Parkinson's disease, and related disorders.